Indication

Muckle-Wells syndrome

Muckle-Wells syndrome is a rare, autosomal dominant autoinflammatory disorder that represents an intermediate phenotypic severity within the spectrum of cryopyrin-associated periodic syndromes. Read more about Muckle-Wells syndrome

5 drugs 4 manufacturers

Advertisement

Drugs that treat it

Common Muckle-Wells syndrome therapies.

Showing 1–5 of 5 drugs

ILARIS (canakinumab/PF)

ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·ACUTE GOUTY ARTHRITIS·+7
Novartis Pharmaceuticals

ARCALYST (rilonacept)

ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·MUCKLE-WELLS SYNDROME·+3
KINIKSA PHARMAC

ILARIS (canakinumab/PF)

ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·ACUTE GOUTY ARTHRITIS·+7
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Muckle-Wells syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Muckle-Wells syndrome.

Muckle-Wells syndrome is a rare, autosomal dominant autoinflammatory disorder that represents an intermediate phenotypic severity within the spectrum of cryopyrin-associated periodic syndromes.

Pathophysiologically, it is driven by gain-of-function mutations in the *NLRP3* (*CIAS1*) gene, which causes hyperactivation of the NLRP3 inflammasome and uncontrolled overproduction of interleukin-1 beta.

Manifesting from infancy or early childhood, the disease is characterized by recurrent systemic inflammatory flares featuring urticaria-like rashes, fevers, arthralgias, and conjunctivitis.

Chronic systemic inflammation frequently leads to progressive complications in adolescence and adulthood, predominantly progressive sensorineural hearing loss and secondary systemic AA amyloidosis that often precipitates renal failure.

Personalize your experience

Follow Muckle-Wells syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it